Endocytosis plays important roles in regulating EGFR signaling. We previously found 11 that EGFR endocytosis during mitosis is mediated differently than during interphase. While the 12 regulation of EGFR endocytosis in interphase is well understood, little is known regarding the 13 regulation of EGFR endocytosis during mitosis. Here, we studied the mechanisms regulating 14 mitotic EGFR endocytosis. We found that contrary to interphase cells, mitotic EGFR endocytosis 15 is more reliant on the activation of the E3 ligase CBL. At high EGF doses, inhibition of inhibited 16 EGFR endocytosis of mitotic cells, but not of interphase cells. Moreover, the endocytosis of 17 mutant EGFR Y1045F-YFP was strongly delayed. The endocytosis of truncated EGFR Δ1044-18 YFP that does not bind to CBL was completely inhibited. EGF induced stronger ubiquitination 19 of mitotic EGFR than interphase EGFR and mitotic EGFR is trafficked to lysosome for 20 degradation. Furthermore, during mitosis low doses of EGF also stimulate EGFR endocytosis by 21 NCE. Contrary to interphase, CBL and the CBL-binding regions of EGFR were required for 22 [14]. At the time, we did not fully decipher the molecular mechanisms behind the differential 56 kinetics. Therefore, in this report, we further studied this phenomenon. 57
The epidermal growth factor (EGF) receptor (EGFR), like other receptor tyrosine kinases 34 (RTKs), regulates key events in cell growth, differentiation, survival and migration [1] [2] [3] . 35
Aberrant signaling from EGFR has been implicated in many diseases [2, 4] . EGFR is historically 36 the prototypical RTK. It was the first of this large family of transmembrane receptors to be 37 cloned, and the first for which a clear connection between aberrant receptor function and cancer 38 could be drawn [2] . The binding of EGF to EGFR at the cell surface induces dimerization of 39 EGFR, which results in the activation of EGFR tyrosine kinase and EGFR trans-40 autophosphorylation [5, 6] . EGFR activation stimulates various signaling pathways that regulate 41 multiple cell functions [1, 3] . EGF stimulates cell proliferation by driving the cell cycle that is 42 comprised of four phases: G1, S, G2 and M [7, 8] . Binding of EGF also stimulates the rapid 43 internalization of EGFR [9] . EGFR endocytosis and EGFR-mediated cell signaling are mutually 44 regulated [10, 11] . 45
In spite of significant advances in our understanding of EGFR signaling and trafficking, 46 some critical knowledge is still lacking. Our current knowledge of EGFR signaling and EGFR 47 endocytosis comes mostly from the studies of cells in G1 phase of the cell cycle. Very little is 48 known regarding EGFR-mediated signaling and endocytosis in mitosis. 49
Mitosis represents a period where the needs and requirements of the cell differ vastly 50 from interphase cells. EGFR signaling has been shown to be regulated differently between 51 interphase and mitotic cells. We and others previously found that the EGFR of mitotic cells can 52 still be activated during mitosis, but that the signal transduction pathways are regulated 53 differently compared to interphase cells [12, 13] . We also previously found that EGFR 54 endocytosis of mitotic cells is regulated differently, in that EGFR is endocytosed at a slower rate 55 5 CBL [32, 35, 36] . Therefore, c-CBL (henceforth CBL) provides a critical negative regulatory 79 control of the EGFR, as it targets the EGFR for endocytosis and degradation. The activation of 80 CBL depends on its binding to the activated EGFR, either by direct interaction with pY1045, or 81 by indirect interaction through the adaptor GRB2, which binds to pY1068 or pY1086 [35, 36, 38, 82 39] . 83
In this report, we find that EGF-stimulated EGFR endocytosis proceeds exclusively by 84 NCE during mitosis. We find that contrary to interphase cells, mitotic EGFR endocytosis is more 85 reliant on the activation of CBL. At high EGF doses, inhibition of CBL by siRNA or mutation 86 inhibited EGFR endocytosis of mitotic cells, but not of interphase cells. Moreover, the 87 endocytosis of truncated EGFR Δ1044-YFP, which does not bind to CBL, was completely 88 inhibited. EGF induced stronger ubiquitination of mitotic EGFR than interphase EGFR and 89 mitotic EGFR is only trafficked to lysosomes for degradation. Furthermore, we found that during 90 mitosis, low doses of EGF also stimulate EGFR endocytosis by NCE. Contrary to interphase, 91 CBL and the CBL-binding regions of EGFR were required for mitotic EGFR endocytosis at low 92 doses. This was due to the mitotic ubiquitination of the EGFR even at low EGF doses. 93
94

MATERIALS AND METHODS 95
Antibodies and chemicals 96
Immunoblotting was performed as previously described [41] . Briefly, protein samples were 148 separated by SDS-PAGE and were transferred to nitrocellulose. The membranes were blocked 149 for non-specific binding, and incubated with primary antibody overnight. The membranes were 150 then probed with HRP-conjugated secondary antibody followed by detection with enhanced 151 chemiluminescence solution (Pierce Chemical, Rockford, IL) and light detection on Fuji Super 152 RX Film (Tokyo, Japan). 153
Indirect immunofluorescence 154
Indirect immunofluorescence was performed as previously described [14] . Cells were grown on 155 glass coverslips and serum-starved for 16 h. After treatment without or with nocodazole (200 156 ng/mL for 16h) and without or with EGF for various indicated times, the cells were fixed with 157 ice cold methanol for 10 min. The cells were then permeabilized with 0.2% Triton X-100 for 10 158 min on ice. Next, cells were blocked with 1% BSA for 1 h on ice. Cells were then incubated with 159 primary antibody overnight at 4°C. Primary antibody anti-CBL was used at 1:50, and anti-160 pEGFR-Y1086 and anti-EGFR were used at 1:200. Cells were then washed three times with 161 PBS, and incubated with rhodamine-or FITC-labeled secondary antibody for 1 h at 4°C. Cells 162 were then washed three times PBS, followed by nuclear staining with DAPI (4´6-diamidino-2-163 phenylindole) (300 nM). Finally, cells were washed three times and mounted. Images were taken 164 with DeltaVision deconvolution microscopy (GE Healthcare Life Sciences, Buckinghamshire). 165 Quantification of EGFR internalization was performed using ImageJ as previously described 166 [14] . Briefly, the cells were visualized by differential interface contrast (DIC). For each image, a 167 large polygon (VL) was drawn along the outer edge of the cell membrane to represent the entire 168 area of the cell. In addition, a small polygon (VS) was drawn along the inner edge of the cell 169 membrane to represent the cell interior. The VL and VS values were calculated for either stains of 170 9 EGFR, pEGFR, or for YFP (for EGFR-YFP mutants), and membrane EGFR percentage was 171 obtained by the following equation: 172 173 174
RESULTS
175
CBL interaction with EGFR during mitosis 176
EGFR expression at the plasma membrane does not change from interphase to mitosis 177 [13, 14, 42] . Previously, we found that similar to interphase, stimulation of nocodazole-arrested 178 mitotic HeLa cells with high doses of EGF (50 ng/mL) induced the phosphorylation of the EGFR 179 at all major tyrosine residues, including Y992, Y1045, Y1068, Y1086, and Y1173 [13] . 180
Moreover, this also phosphorylated CBL to similar levels [13] . 181
To confirm mitotic CBL activation by EGF stimulation, we observed CBL localization in 182 mitotic HeLa cells by immunofluorescence microscopy. Immunofluorescence co-staining using 183 anti-EGFR and anti-CBL antibodies revealed that CBL co-localizes with EGFR upon 5 min of 184 50 ng/mL EGF treatment in both interphase and mitotic cells ( Figure 1A) . Furthermore, 185 immunoprecipitation of EGFR using a monoclonal anti-EGFR antibody of both interphase and 186 mitotic cell lysates showed that mitotic cells stimulated with EGF for 5 mins had higher IPs of 187 CBL with EGFR than interphase cells ( Figure 1B) . Interestingly, CBL IP with EGFR decreased 188 after 30 min EGF in mitotic cells, whereas it increased for interphase cells, and continued 189 increasing at 45 mins EGF. Most surprisingly however, was that ubiquitination of the EGFR was 190 enhanced at all time points studied during mitosis compared to interphase (Figure 1B) . Since 191 CBL also binds EGFR indirectly through the EGFR adaptor GRB2, we also immunoblotted 192 10 EGFR immunoprecipitates for GRB2 and SHC. The results showed that during mitosis, GRB2 193 and SHC also bind to EGFR following EGF stimulation (Figure 1B) . 194
In summary, double indirect immunofluorescence revealed that both localize after EGF stimulation during mitosis. Co-IP experiments also showed that EGF 196 stimulated the interaction between EGFR and CBL. In addition, EGFR is more strongly 197 ubiquitinated by EGF stimulation during mitosis. 198
Effects of altering CBL activity during mitosis 199 CME has been shown to be inhibited during mitosis [27, 29, 30] . Therefore, we sought to 200 discover whether altering CBL activity, the major mediator of NCE, would inhibit EGFR 201 endocytosis. We first silenced CBL in HeLa cells by siRNA transfection and found that 202 transfected mitotic cells had much less EGFR endocytosis following EGF (50 ng/mL) 203 stimulation, as observed by immunofluorescence (IF) staining of activated EGFR (Figure 2A) . 204
In comparison, transfected interphase cells were little affected. Similarly, in MCF-7 cells 205 transfected with EGFR-YFP knockdown CBL by siRNA also inhibited mitotic endocytosis of 206 EGFR (Figure 2B) . To further verify the role of CBL, we used the dominant-negative 70Z-CBL-207 YFP mutant, which has a deletion of 17 amino acids that disrupts the RING finger structure 208 making it unable to interact properly with ubiquitin-conjugating enzymes (E2 ligases) [43, 44] . 209
The 70Z-CBL-YFP protein can still bind to the cytoplasmic tail of activated EGFR [43, [45] [46] [47] . 210
Transfection with 70Z-CBL-YFP significantly inhibited EGF-induced EGFR endocytosis during 211 mitosis, but not in interphase ( Figure 3A) . Quantification of the data from Figure 3A showed 212 that mitotic cells transfected with 70Z-CBL-YFP retained EGFR at the plasma membrane when 213 compared with non-transfected cells, even after 60 minutes of EGF treatment (50 ng/mL) 214 ( Figure 3B) . Taken together, downregulating CBL activity decreased EGFR endocytosis in 215 11 mitosis, but not in interphase. Therefore, CBL activity appears more important during mitotic 216 EGFR endocytosis than during interphase. 217
We next sought to see whether CBL overexpression could increase the rate of 218 endocytosis during mitosis. CBL overexpression in HeLa cells did not appear to induce 219 endocytosis at earlier time points, nor increase the rate of EGFR internalization (Figure 3C) . 220 This is similar to interphase cells, where it was previously reported that overexpression of CBL 221 did not increase the rate of EGFR internalization [46, 48] . 222
Role of EGFR C-terminal domains for mitotic endocytosis 223
We previously showed that mitotic EGFR endocytosis requires EGFR kinase activity 224 [14] . Treatment with the EGFR-tyrosine kinase antagonist AG1418 inhibited mitotic EGFR 225 endocytosis, and washing away AG1478 restored endocytosis [14] . In contrast, interphase EGFR 226 could still undergo endocytosis in the presence of AG1478 [14] . To further explore the role of 227 EGFR kinase activity in the activation of CBL, we blocked EGFR activation with AG1478 for 1 228 h prior to EGF (50 ng/mL) treatment. As before, this treatment prevented EGFR endocytosis 229 during mitosis as visualized by IF [14] (data not shown). We next examined CBL 230 phosphorylation by immunoblotting with antibody to p-CBL and showed that treatment with 231 AG1478 inhibited EGF-induced CBL tyrosine phosphorylation in mitotic cells. (Figure 4A) . 232 Therefore, EGFR kinase activity is required for CBL activation. 233
We next sought to investigate which EGFR domains were important for mitotic 234 endocytosis. We made use of previously constructed YFP-tagged EGFR mutants including 235 EGFR with Y1045F substitution (Y1045F-YFP, no direct CBL binding), EGFR truncated at 236 1045 (Δ1044-YFP, no CBL binding), EGFR truncated at 992 (Δ991-YFP, no internalization), 237 and WT (EGFR-YFP) ( Figure 5F ). We transfected these constructs into MCF-7 or HEK 293T 12 cells, since they express low amounts of endogenous EGFR, then observed the effects of EGF 239 treatment on their plasma membrane localization using indirect immunofluorescence ( Figure  240 4B-E & Figure 5A -E). 241
In non-EGF treated MCF-7 cells, all mutants exhibited high plasma membrane 242 localization and low cytoplasmic localization during both interphase and mitosis (Figure 5A-E) . 243
For the cells in the interphase, treatment of EGF (50 ng/mL) for 30, 45, or 60 mins significantly 244 increased the internalization of EGFR-YFP, Y1045F-YFP, and Δ1044-YFP, but not Δ991-YFP 245 which is endocytosis deficient due to the lack of internalization motifs. The internalization levels 246 of EGFR-YFP, Y1045F-YFP, and Δ1044-YFP during interphase at all three time points were all 247 similar. In contrast, these mutants responded to EGF treatment differently from each other when 248 cells were in mitosis. For the cells in mitosis, EGF stimulated strong endocytosis of EGFR-YFP, 249 approximately two-thirds of EGFR-YFP was internalized following 30 min EGF treatment, with 250 more EGFR-YFP becoming internalized at 45 and 60 min. The internalization of both Y1045F-251 YFP and Δ1044-YFP however were impaired in mitosis. In mitosis, no endocytosis of Y1045F-252 YFP mutants was observed following addition of EGF for 30 min, and only very low level of 253 EGFR endocytosis at 45 min. Interestingly, a high proportion of them eventually became 254 endocytosed at 60 min. However, no EGF-induced endocytosis of Δ1044-YFP mutants was 255 observed even at 60 min following EGF addition ( Figure 5 ). Similar results were observed when 256 the experiments were repeated in 293T cells (Figure 4B-E) . 257
Taken together, this data shows that the CBL-binding domains of the EGFR are more 258 important for mitotic EGFR endocytosis than interphase. These results also suggest that GRB2 259 cooperation for indirect CBL-binding to EGFR dramatically increases mitotic EGFR 260 endocytosis. 261
Endocytic trafficking of EGFR in mitosis 262
The endocytic pathway that the EGFR takes has been shown to influence the fate of the 263 EGFR. CME has been shown to lead to EGFR recycling, whereas NCE targets receptors for 264 lysosomal degradation [35, 36] . Since we observed that EGFR endocytosis during mitosis 265 proceeds exclusively in CBL-mediated NCE, we hypothesized that EGFR endocytosis during 266 mitosis should lead exclusively to lysosomal trafficking. To test this, we examined the co-267 localization of endocytic route markers with EGFR by fluorescence microscopy. The EGFR of 268 both mitotic and interphase cells showed strong co-localization with EEA-1 and RAB5 after 30 269 min EGF treatment, indicating that the EGFR is trafficked to early endosomes (Figure 6) . EEA-270 1 and RAB5 did not co-localize with any EGFR at the plasma membrane of either mitotic or 271 interphase cells. Staining with the late endosomal markers LAMP-2 showed that EGFR and 272 LAMP-2 colocalized after EGF stimulation for 60 min. These data indicated that EGFR was 273 targeted to lysosomes through NCE during mitosis. 274 275
Low EGF doses activate mitotic EGFR NCE 276
The above experiments were all performed using high concentrations of EGF (50 277 ng/mL). During interphase, low doses of EGF only activates CME, whereas high doses activate 278 both CME and NCE [32, 35, 36] . If this finding is also applied to mitosis, low doses of EGF 279 should not induce EGFR endocytosis in mitosis as CME is inhibited in mitosis and only high 280 doses of EGF activates NCE. However, we previously observed that low doses TR-EGF (2 281 ng/mL) could still lead to their internalization in mitotic HeLa and CHO cells in a similar pattern 282 as high dose of EGF [14] . We therefore decided to determine if EGFR endocytosis at both high 283 and low dose of EGF are regulated by CBL-mediated NCE. 284
14
We hypothesized that similar to high dose, low dose EGF is still able to stimulate EGFR 285 endocytose through NCE in mitosis. To test this hypothesis, we first repeated experiments 286 described in Figure 3 -5 with low dose of EGF (2 ng/ml), and we indeed obtained similar results 287 ( Figure 6-7) . As shown in Figure 6 , in MCF-7 cells transfected with EGFR-YFP, EGF at low 288 dose (2 ng/mL) induced EGFR endocytosis in both interphase and mitotic cells (Figure 7) . The 289 endocytosis of Y1045F-YFP was only observed at 60 min following EGF addition in mitosis, 290 and Δ1044-YFP was deficient in endocytosis during mitosis (Figure 7) . These data suggest that 291 at low dose EGF, mitotic EGFR endocytosis require its interaction with CBL. To further 292 determine the involvement of CBL in low dose EGF-stimulated EGFR endocytosis in mitosis, 293
we transfected Hela cells with either wild type CBL-YFP or non-functional 70z-YFP (Figure 8) . 294
As in high dose EGF conditions, expression of 70z-YFP inhibited EGFR endocytosis in response 295 to low dose EGF. However, expression of CBL-YFP did not affect EGFR endocytosis in mitosis 296 in response to low dose EGF. Together these data suggest that EGFR endocytosis induced by 297 low dose EGF is also mediated by CBL 298
We then examined why low dose EGF is able to stimulate EGFR endocytosis through 299 CBL-mediated NCE in mitosis, but not in interphase. We examined whether this is due to CBL-300 mediated ubiquitination of EGFR. To this end, we treated Hela cells with EGF at 2 ng/mL or 50 301 ng/mL for 45 min and examined the ubiquitination of EGFR in both interphase and mitosis 302 ( Figure 9A) . Co-immunoprecipitation of EGFR and immunoblotting for ubiquitin revealed that 303 as before, high dose EGF (50 ng/mL) induced higher EGFR ubiquitination in mitosis more than 304 in interphase. Low dose EGF (2 ng/mL) did not induce the ubiquitination of EGFR in interphase, 305 as previously reported [32, 35, 36 ]. However, low dose EGF stimulation caused significant 306 EGFR ubiquitination in mitotic cells. Moreover, the binding of CBL to EGFR followed the same 307 15 pattern as ubiquitination, with CBL again binding to EGFR at low doses during mitosis, but not 308 during interphase. 309
We also performed similar experiments with different times of EGF stimulation, at 5, 30, 310 and 45 mins ( Figure 9B) . The phosphotyrosine-specific antibody pY99 was used to confirm 311 EGFR phosphorylation. Blotting for ubiquitin revealed that during mitosis ubiquitination of 312 EGFR occurred at 5 mins, and is sustained through to 45 mins in response to low dose EGF 313 stimulation. In contrast, in interphase EGFR ubiquitination only occurred briefly at 5 min, 314 ubiquitination was very weak at later time points. In addition, CBL and SHC are pulled-down 315 with EGFR during both interphase and mitotic. Therefore, it appears that low dose EGF 316 stimulation differentially ubiquitinates mitotic EGFR, and not interphase EGFR. 317
Since mitotic EGFR is strongly ubiquitinated at low doses of EGF, and ubiquitination has 318 been associated with EGFR degradation, we hypothesized that low EGF doses could lead to 319 EGFR degradation during mitosis. Total cell lysates of interphase and mitotic cells treated with 320 low doses of and total EGFR levels were assayed by Western blot. Whereas interphase EGFR 321 levels remain constant throughout 45 mins of low dose EGF treatment, we found that mitotic 322 EGFR levels drop drastically with time ( Figure 9C) . Taken together, these results suggest that, 323 unlike interphase, low doses of EGF activate CBL-mediated EGFR degradation in mitotic cells. 324
Interestingly, by Western blotting, the CBL band appears smaller in mitotic samples than 325 interphase samples. 326
DISCUSSION 327
Our results showed that EGF-induced EGFR endocytosis during mitosis proceeds 328 exclusively by CBL-dependent NCE (Figure 10) . NCE plays a major role in the regulation of 329 EGFR fate by targeting it to lysosomes for degradation. Our research has uncovered a temporal 330 16 period by which to exclusively target EGFR for degradation. This bypasses the receptor 331 recycling pathway that is undesirable if the goal is EGFR attenuation, or if it is to deliver and 332 keep a pharmacological agent into a cell [49] . Targeting mitotic cells is feasible for EGFR-333 overexpressing cancer cells, as these cells intrinsically undergo more cell proliferation. In 334 addition, the population of mitotic cells can be increased by treatment with anti-mitotic drugs, 335 such as the commonly used taxanes and vinca alkaloids. Therefore, mitotic cells of EGFR-336 overexpressing cells can be targeted more directly. Moreover, the FDA-approved EGFR 337 antibody cetuximab has been shown to initiate receptor endocytosis [50] . Whether mitotic 338 EGFR treated with EGFR antibodies are also internalized by NCE remains to be investigated. 339
However, if it does, nano-conjugation of EGFR antibodies to pharmacological agents may 340 provide a targeted approach to treating these cancers. 341
The study of EGFR NCE thus far has relied on the inhibition of clathrin, as well as the 342 use of high doses of EGF to activate NCE. Our results indicate that mitotic EGFR endocytosis is 343 exclusively through NCE. Thus, mitotic cells offer an alternate system for studying the NCE of 344 the EGFR regardless of EGF dosage. In general, NCE is much more complicated and very little 345 understood. It is no surprise that very little is known regarding the regulation of mitotic NCE of 346 EGFR. Our findings that mitotic EGFR endocytosis is mediated by CBL through NCE at both 347 high and low dose of EGF advanced our understanding on both EGFR endocytosis and NCE in 348 general. 349
The theory that EGFR ubiquitination is absolutely necessary for endocytosis has been a 350 subject of controversy [51] [52] [53] [54] . Our research supports the notion that ubiquitination by CBL is 351 important for NCE [32, 36] . Furthermore, our research provides strong support for the 352 requirement of CBL and GRB2 binding to the EGFR in order to cause its ubiquitination [35, 36] . 353
Our results argue that GRB2-mediated CBL binding is more important than direct CBL-binding 354 during mitosis, as the internalization of Δ1044 mutant had significantly inhibited, whereas the 355 internalization of Y1045F mutant had only slightly inhibited. Overexpression of CBL did not 356 accelerate nor enhance mitotic EGFR endocytosis in response to EGF. This has also been 357 recently demonstrated by in vivo experiments [55] . NCE has been reported to initiate more 358 slowly than CME [9, 32-34, 43, 56] , and it therefore appears that CBL overexpression is not the 359 limiting factor to the speed of EGFR NCE. Other important mediators of NCE, for example 360 EPS15, EPS15R, and EPSIN [32], or endoplasmic reticulum (ER)-resident protein reticulon 3 361 (RTN3) and CD147 [57] may warrant investigation. More importantly, the exact mechanism by 362 which the ubiquitination of the EGFR induces internalization is still unknown, and studies to 363 elucidate the precise molecular mechanism would be extremely impactful. 364
The inactivation of CBL has been shown to display pro-oncogenic features [58] [59] [60] [61] [62] . 365
Moreover, common pro-oncogenic EGFR mutations L858R and L858R/T790M have impaired 366 CBL-binding, slower endocytosis, and impaired degradation [63] . EGFRvIII, the most common 367 variant in gliomas, also has a reduced interaction with CBL and thus impaired ubiquitination 368 owing to hypophosphorylation of pY1045 [64, 65] . Here, we showed that CBL activity during 369 mitosis is even more important, and its activity is enhanced compared to interphase cells. 370
Evolutionarily, since mitotic cells do not have active CME [27, 29] , the activation of NCE may 371 have been even more critical during mitosis to suppress EGFR overactivation. A loss of CBL 372 activity, whether by inactivating mutations to CBL or EGFR CBL-binding, would therefore have 373 a more pronounced effect during mitosis, as the EGFR would continue to signal excessively. The 374 functional role of mitotic EGFR activation is still not well known. It is unclear how abnormally 375 18 sustained EGFR signaling during mitosis affects cellular processes, however, it does appear to 376 help mitotic cancer cells resist nocodazole-mediated cell death [13] . 377
We showed that the EGFR is more strongly ubiquitinated during mitosis at both low and 378 high doses of EGF, suggesting that CBL activity is enhanced during mitosis. How can CBL be 379 better primed to induce endocytosis, even at low concentrations of EGF during mitosis? It has 380 been shown that CBL also acts as an adaptor in the CME pathway. Since CME is no longer 381 active during mitosis, a possible explanation may be due to increased CBL protein availability, 382 as the cellular pool of CBL no longer needs to divide its time between CME and NCE. Another 383 explanation may be that CBL is modified during mitosis to be better primed for its E3 ligase 384 activity. Interestingly, probing with the CBL antibody revealed that the mitotic CBL band 385 appears smaller compared to interphase (Figure 8) , although the exact significance is unknown. 386
Another alternative possibility may revolve around the DUBs (deubiquitinating enzymes) that 387 deubiquitinate EGFR. Fifteen DUBs have been reported to impact EGFR fate, although some 388 may be deubiquitinating non-EGFR component, such as EPS15 [66] . These DUBs could be shut 389 off during mitosis, causing ubiquitination to persist longer than during the interphase. 390
Mitosis represents a phase of tremendous transition to the cell. A significant change is the 391 global phosphorylation of mitotic proteins by mitotic kinases. For example, studies have shown 392 the mitotic phosphorylation of over 1000-6027 proteins, including 14,000-50,000 393 phosphorylation events depending on the study [67] [68] [69] . Interestingly, many phospho-sites 394 overlap between EGF-stimulated cells and mitotic cells [69] . Indeed, various components of the 395 EGFR signaling and endocytic pathways appear to play different roles in mitosis, a phenomenon 396 known as moonlighting [28, 70] . This includes important members of EGFR CME, such as 397 clathrin, dynamin, and AP-2 [28, [71] [72] [73] [74] . Since these proteins and many others are moonlighting 398 19 in mitosis-related processes, their availability to participate in EGFR endocytosis during mitosis 399 may be compromised. This may also affect EGFR signaling. It has been shown that EGF-400 induced AKT activation requires EGFR residence in clathrin coated pits, but not internalization 401 [75, 76] . We previously showed that only AKT2, and not AKT1, becomes activated following 402 EGF stimulation during mitosis [13] . Since CME is shut down during mitosis, it can be 403 speculated that the differential activation of AKT during mitosis is a consequence of the inability 404 of clathrin to be involved in mitotic EGFR endocytosis. Therefore, the changes imparted by 405 global mitotic phosphorylation and mitotic cell rounding cannot be discounted to EGFR 406 signaling, and likely of other signaling receptors as well. 407
In our study, we made use of the microtubule depolymerizer nocodazole to arrest cells in 408 mitosis. So far, nocodazole is still the most widely used drug for arresting cells in mitosis [69, 409 77-79] . We decided to use nocodazole in our research in order to obtain synchrony between our 410
Western blots, co-IPs, and immunofluorescence experiments, as it has been shown that the sub-411 stage of mitosis can influence the kinetics of endocytosis [14] . Previous research has showed that 412 factors such as serum starvation, nocodazole, and other mitotic inhibitors could inhibit CME 413 [80] . However, it should be noted that the researchers were evaluating transferrin receptors, 414 which is endocytosed by constitutive endocytosis rather than the ligand-induced mechanism used 415 by EGFR. Furthermore, our previous study that showed that clathrin downregulation by siRNA 416 had no effect on mitotic EGFR endocytosis was performed without the use of nocodazole [14] . 417
We have also previously shown that 16 h nocodazole treatment does not lead to significant cell 418 apoptosis [13] . 419
The EGFR uses various signaling pathways to achieve numerous pro-oncogenic cellular 420 outcomes. Endocytosis downregulates EGFR signaling from the cell surface, but initiates 421 20 intracellular signaling from endosomes [81] . In this way, endocytosis controls EGFR signaling, 422 spatially and temporally, making it an indispensable part of receptor signaling. Therefore, the 423 interplay between EGFR signaling and endocytosis critically determines cellular outcome. 424
In conclusion, our research further showed that mitotic EGFR endocytosis proceed through 425 CBL-mediated NCE, which supports the notion that mitotic endocytosis is not completely 426 inhibited, but proceeds through NCE. The unique property of mitotic EGFR endocytosis offers 427 an important opportunity for developing cancer therapy that targets both EGFR and mitosis. ng/mL) only activates clathrin-mediated endocytosis (CME), leading to receptor recycling. High 517 EGF doses (>20 ng/mL) also activates CME, but can also activate non-clathrin mediated 518 endocytosis (NCE) due to the dose-dependent activation of CBL and EGFR ubiquitination. NCE 519 leads to lysosomal degradation of EGFR. In mitotic cells, CME is shut off. Therefore, EGFR 520 endocytosis must proceed by NCE. Both low and high concentrations of EGF activate NCE 521 during mitosis, and this may be because contrary to interphase cells, low EGF concentrations can 522 activate CBL and EGFR ubiquitination. Therefore, mitotic EGFR endocytosis leads exclusively 523 to lysosomal degradation. 
